Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 4.7%

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) fell 4.7% during mid-day trading on Friday . The company traded as low as $14.73 and last traded at $15.01. 384,877 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 631,468 shares. The stock had previously closed at $15.75.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $40.60.

Day One Biopharmaceuticals Stock Performance

The company’s fifty day moving average price is $15.24 and its 200 day moving average price is $13.68. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -6.62 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $16.01, for a total value of $160,100.00. Following the sale, the insider now directly owns 1,184,662 shares in the company, valued at approximately $18,966,438.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. Insiders sold 45,781 shares of company stock worth $722,960 in the last 90 days. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of DAWN. Hennion & Walsh Asset Management Inc. grew its position in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after buying an additional 1,445 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 4,769,746 shares of the company’s stock worth $69,638,000 after acquiring an additional 139,992 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of Day One Biopharmaceuticals by 89.0% in the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after acquiring an additional 32,238 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Day One Biopharmaceuticals by 77.7% in the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after acquiring an additional 91,393 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. 87.95% of the stock is currently owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.